OBJECTIVES: To characterise the epidemiology and outcome of people hospitalised with a primary diagnosis of psoriasis has never been characterised previously in the UK. METHODS: Routine hospital data from a large geographical area (population approx. 435,000) were record-linked using probability matching algorithms to mortality data from the Office of National Statistics (1991 to 2005). Relative survival was compared using Cox proportional hazards models. RESULTS: It was possible to identify 1935 hospital admissions from 1038 subjects; 49% male. The mean age at first admission was 44 years (sd 20). The minimum, crude prevalence of people hospitalised with psoriasis at some time was 0.23%. Coincidentally, these admissions represent...
Background: Scottish Intercollegiate Guidelines Network and National Institute of Health and Care Ex...
Background: Psoriasis is a common, lifelong inflammatory skin disease, the severity of which can ran...
Background: Immunologic alterations caused by psoriasis and/or its therapies may affect the risk of ...
OBJECTIVES: To characterise the epidemiology and outcome of people hospitalised with a primary diag...
OBJECTIVES: To characterise the epidemiology and outcome of people hospitalised with a primary diag...
Background: The epidemiology and outcome of people hospitalised with a primary diagnosis of psoriasi...
Background: The epidemiology and outcome of people hospitalised with a primary diagnosis of psoriasi...
Objective To determine the risk of mortality in patients with psoriasis. Design Cohort study. Sett...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
Background: Psoriasis is the most common T helper 1 mediated inflammatory disease, affecting more th...
Background: People with psoriasis live with other long‐term conditions (comorbidities)that affect th...
Background: Scottish Intercollegiate Guidelines Network and National Institute of Health and Care Ex...
Background: Psoriasis is a common, lifelong inflammatory skin disease, the severity of which can ran...
Background: Immunologic alterations caused by psoriasis and/or its therapies may affect the risk of ...
OBJECTIVES: To characterise the epidemiology and outcome of people hospitalised with a primary diag...
OBJECTIVES: To characterise the epidemiology and outcome of people hospitalised with a primary diag...
Background: The epidemiology and outcome of people hospitalised with a primary diagnosis of psoriasi...
Background: The epidemiology and outcome of people hospitalised with a primary diagnosis of psoriasi...
Objective To determine the risk of mortality in patients with psoriasis. Design Cohort study. Sett...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
International audienceBackground: Data on treatment exposures for psoriasis and poor COVID-19 outcom...
Background: Psoriasis is the most common T helper 1 mediated inflammatory disease, affecting more th...
Background: People with psoriasis live with other long‐term conditions (comorbidities)that affect th...
Background: Scottish Intercollegiate Guidelines Network and National Institute of Health and Care Ex...
Background: Psoriasis is a common, lifelong inflammatory skin disease, the severity of which can ran...
Background: Immunologic alterations caused by psoriasis and/or its therapies may affect the risk of ...